Literature DB >> 23645382

Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries.

Xu Steven Xu1, Mahesh N Samtani, Adrian Dunne, Partha Nandy, An Vermeulen, Filip De Ridder.   

Abstract

Beta regression models have been recommended for continuous bounded outcome scores that are often collected in clinical studies. Implementing beta regression in NONMEM presents difficulties since it does not provide gamma functions required by the beta distribution density function. The objective of the study was to implement mixed-effects beta regression models in NONMEM using Nemes' approximation to the gamma function and to evaluate the performance of the NONMEM implementation of mixed-effects beta regression in comparison to the commonly used SAS approach. Monte Carlo simulations were conducted to simulate continuous outcomes within an interval of (0, 70) based on a beta regression model in the context of Alzheimer's disease. Six samples per subject over a 3 years period were simulated at 0, 0.5, 1, 1.5, 2, and 3 years. One thousand trials were simulated and each trial had 250 subjects. The simulation-reestimation exercise indicated that the NONMEM implementation using Laplace and Nemes' approximations provided only slightly higher bias and relative RMSE (RRMSE) compared to the commonly used SAS approach with adaptive Gaussian quadrature and built-in gamma functions, i.e., the difference in bias and RRMSE for fixed-effect parameters, random effects on intercept, and the precision parameter were <1-3 %, while the difference in the random effects on the slope was <3-7 % under the studied simulation conditions. The mixed-effect beta regression model described the disease progression for the cognitive component of the Alzheimer's disease assessment scale from the Alzheimer's Disease Neuroimaging Initiative study. In conclusion, with Nemes' approximation of the gamma function, NONMEM provided comparable estimates to those from SAS for both fixed and random-effect parameters. In addition, the NONMEM run time for the mixed beta regression models appeared to be much shorter compared to SAS, i.e., 1-2 versus 20-40 s for the model and data used in the manuscript.

Entities:  

Mesh:

Year:  2013        PMID: 23645382     DOI: 10.1007/s10928-013-9318-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  11 in total

1.  A comparison of three random effects approaches to analyze repeated bounded outcome scores with an application in a stroke revalidation study.

Authors:  Marek Molas; Emmanuel Lesaffre
Journal:  Stat Med       Date:  2008-12-30       Impact factor: 2.373

2.  Estimating transformations for repeated measures modeling of continuous bounded outcome data.

Authors:  Matthew M Hutmacher; Jonathan L French; Sriram Krishnaswami; Sujatha Menon
Journal:  Stat Med       Date:  2011-01-13       Impact factor: 2.373

3.  An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.

Authors:  Mahesh N Samtani; Michael Farnum; Victor Lobanov; Eric Yang; Nandini Raghavan; Allitia Dibernardo; Vaibhav Narayan
Journal:  J Clin Pharmacol       Date:  2011-06-09       Impact factor: 3.126

4.  Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database.

Authors:  K Ito; M M Hutmacher; B W Corrigan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-09-19       Impact factor: 2.745

5.  Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis.

Authors:  James A Rogers; Daniel Polhamus; William R Gillespie; Kaori Ito; Klaus Romero; Ruolun Qiu; Diane Stephenson; Marc R Gastonguay; Brian Corrigan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-21       Impact factor: 2.745

6.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

Authors:  I Gélinas; L Gauthier; M McIntyre; S Gauthier
Journal:  Am J Occup Ther       Date:  1999 Sep-Oct

7.  Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database.

Authors:  Kaori Ito; Brian Corrigan; Qinying Zhao; Jonathan French; Raymond Miller; Holly Soares; Elyse Katz; Timothy Nicholas; Bill Billing; Richard Anziano; Terence Fullerton
Journal:  Alzheimers Dement       Date:  2010-09-01       Impact factor: 21.566

8.  Bounded outcome score modeling: application to treating psoriasis with ustekinumab.

Authors:  Chuanpu Hu; Newman Yeilding; Hugh M Davis; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-06-18       Impact factor: 2.745

9.  Disease progression meta-analysis model in Alzheimer's disease.

Authors:  Kaori Ito; Sima Ahadieh; Brian Corrigan; Jonathan French; Terence Fullerton; Thomas Tensfeldt
Journal:  Alzheimers Dement       Date:  2009-07-09       Impact factor: 21.566

Review 10.  Neuroimaging outcomes for clinical trials.

Authors:  G B Frisoni; A Caroli
Journal:  J Nutr Health Aging       Date:  2007 Jul-Aug       Impact factor: 4.075

View more
  7 in total

1.  Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.

Authors:  Xu Steven Xu; Mahesh Samtani; Min Yuan; Partha Nandy
Journal:  AAPS J       Date:  2014-08-28       Impact factor: 4.009

2.  Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model.

Authors:  Mario Nagase; Sameer Doshi; Sandeep Dutta; Chih-Wei Lin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-07-23       Impact factor: 2.410

3.  An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.

Authors:  Daniela J Conrado; William S Denney; Danny Chen; Kaori Ito
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-29       Impact factor: 2.745

4.  Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Mahesh N Samtani; Nandini Raghavan; Gerald Novak; Partha Nandy; Vaibhav A Narayan
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-24       Impact factor: 2.570

5.  Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.

Authors:  Steven X Xu; Mahesh N Samtani; Alberto Russu; Omoniyi J Adedokun; Ming Lu; Kaori Ito; Brian Corrigan; Sangeeta Raje; H Robert Brashear; Scot Styren; Chuanpu Hu
Journal:  Alzheimers Dement (N Y)       Date:  2015-07-21

6.  Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.

Authors:  Mahesh N Samtani; Steven X Xu; Alberto Russu; Omoniyi J Adedokun; Ming Lu; Kaori Ito; Brian Corrigan; Sangeeta Raje; H Robert Brashear; Scot Styren; Chuanpu Hu
Journal:  Alzheimers Dement (N Y)       Date:  2015-10-09

7.  A Bounded Integer Model for Rating and Composite Scale Data.

Authors:  Gustaf J Wellhagen; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.